Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice - Dizdarevic, S; Petersen, PM; Essler, M; Versari, A; Bourre, JC; la Fougere, C (Eur J Nucl Med Mol Imaging, 2019)
et al.